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Chronic obstructive pulmonary disease (COPD) is a debilitating pulmonary disorder with systemic eﬀects, and it is the fourth
leading cause of death in the United States. COPD patients not only develop respiratory limitations, but can also demonstrate
systemic wasting, features of depression, and can succumb to social isolation.Smoking cessation is crucial, and pharmacotherapy
with bronchodilators is helpful in symptom management. Inhaled corticosteroids may be beneﬁcial in some patients. In addition,
pulmonary rehabilitation and palliative care are important components under the right clinical circumstance. This review
highlights current guidelines and management strategies for COPD and emphasizes novel pharmacotherapy and minimally
invasive (nonsurgical) lung-volume reduction interventions that may prove to be of signiﬁcant beneﬁt in the future.
1.Epidemiology
Chronic obstructive pulmonary disease (COPD) is a syn-
drome characterized by chronic and progressive airﬂow
reduction that is scarcely reversible and by inﬂammation of
the small airways. It is the potential functional consequence
of two diseases that can often coexist in the same patient,
such as panlobular emphysema and ﬁbrosing chronic bron-
chiolitis with or without signiﬁcant centrilobular emphy-
sema. It can also include chronic bronchitis (the presence
of a chronic productive cough for 3 months or more in
each of 2 consecutive years) [1, 2]. Chronic bronchitis per
se is a smoking related disease of large airways that often
resolves after smoking cessation. Nevertheless, patients with
COPD who suﬀer from chronic bronchitis generally show
faster functional decline, more exacerbations, and greater
morbidity and mortality. Furthermore, a greater percentage
of subjects with chronic cough and phlegm who continue to
smoke can have COPD as compared with smokers without
symptoms when functionally reassessed after 8 years [3].
However, the majority of patients with chronic bronchitis
will not suﬀer from COPD [2, 3]. Therefore, chronic
bronchitis itself can be considered as both a risk factor for
COPD, and a worse prognostic factor in the presence of
COPD.
COPD typically progresses over time and is associated
with an increased inﬂammatory response of the lung to
continued environmental exposures which is often tobacco
smoke [4]. The natural history of COPD is punctuated
by breathlessness especially on exertion with daily activities
of normal living, increased production and purulence of
sputum,overallhealthdecline,andepisodesofexacerbations
that require medical attention and hospitalizations.
While the prevalence of COPD varies by country, it is
generally linked to the prevalence of tobacco smoking. There
is also a link to air pollution from the burning of wood and
otherbiomass fuels [4]. The prevalenceof chronic bronchitis
among adults from 1999–2008 ranged from 34 (2007) to 55
(2001)casesper1,000populationintheUnitedStates(USA).
The range over the same time period for emphysema was
14 (1999) to 18 (2006) cases per 1,000 population [5]. In
2008, females had twice the reported prevalence of chronic
bronchitis than males (58 versus 29 cases per 1,000 resp.).
Emphysematous males have a slightly higher prevalencethan2 Pulmonary Medicine
females (17 compared to 16 cases per 1,000, resp.) [5].
Gender diﬀerences may separate clinical COPD phenotypes
and is typical of the heterogeneity in COPD.
Worldwide, COPD is one of the leading cause of
morbidity and mortality [4]. COPD is the 4th leading cause
of mortality in the USA, and is also the only one of the
top ﬁve leading causes of death that is continuing to rise,
doubling from 1970 to 2002 [6]. It is projected that COPD
will become the third leading cause of death worldwide
by 2020 [4]. Furthermore, COPD deaths among women in
the USA have been rapidly rising since the 1970s and have
exceeded male COPD deaths since 2000 [4, 7].
COPD presents an increasing social and economic bur-
den. COPD patients incur health care costs associated with
frequent clinic visits, urgent care visits, and hospitalizations.
Home medical therapies, including oxygen therapy, visiting
nursing services, and rehabilitation add to the cost [4].
The health-care expenditure for each COPD patient cost on
average $6,000 annually [8]. In 2002, the estimated USA
direct medical cost of COPD was $18 billion while indirect
costs including lost wages and decreased productivity were
estimated at $14.1 billion [4].
2.CurrentTreatmentGuidelines
The goals of COPD treatment are to arrest or at least reduce
its progression, control symptoms, and to prevent acute
COPD exacerbations in an attempt to improve overall mor-
tality. Smoking cessation, pharmacotherapy, and pulmonary
rehabilitation form the cornerstones of COPD management.
2.1. Smoking Cessation. Smoking cessation programs and
education should be available and encouraged for all
smokers. The Global Initiative for Chronic Obstructive
Lung Disease (GOLD) guidelines emphasize that smoking
cessation is “the single most eﬀective and cost-eﬀective
way to reduce exposure to COPD risk factors [4].” In a
randomized, controlled trial of a 10-week-long smoking
cessationprogramin5887smokerswithasymptomaticmild-
moderate airway obstruction, the 14-year all-cause mortality
rates in the smoking cessation group was lower than in the
usual care group (HR 1.18; CI 1.02–1.37) [9]. In addition
to counseling, a variety of eﬀective pharmacotherapies for
smoking cessation are available for patients, the details of
which are beyond the scope of this review.
2.2. Pharmacotherapy. GOLD has classiﬁed COPD into four
stages based on spirometric values and thus on severity
of airﬂow obstruction (Table 1)[ 4]. The focus of COPD
treatment should be relief of symptoms, improving exercise
tolerance and overall health status, prevention and timely
treatment of exacerbations, preventing disease progression,
and reducing mortality [4]. Pharmacologic therapy is able
to signiﬁcantly improve the quality of life and reduce the
frequency of exacerbations, but is unable to halt the annual
decline in FEV1 or unequivocally reduce mortality, with the
important exception ofoxygentherapy where indicated[10].
Table 1: Spirometric classiﬁcation of COPD severity: gold staging
criteria.
Stage I: mild FEV1/FVC < 0.70
FEV1 ≥ 80% predicted
Stage II: moderate FEV1/FVC < 0.70
50% ≤ FEV1 < 80% predicted
Stage III: severe FEV1/FVC < 0.70
30% ≤ FEV1 < 50% predicted
Stage IV: very severe FEV1/FVC < 0.70
FEV1 < 30% predicted or FEV1 < 50%
predicted plus chronic respiratory failure
FEV1: forced expiratory volume in the ﬁrst second (postbronchodilator).
FVC: forced vital capacity.
Respiratory failure: arterial partial pressure of oxygen (PaO2)l e s st h a n
8.0kPa (60mmHg) with or without arterial partial pressure of CO2
(PaCO2) greater than 6.7kPa (50mmHg) while breathing air at sea level.
Adapted from http://www.goldcopd.com/, updated 2009.
Bronchodilators are the mainstay for the symptomatic
management of COPD.While theydonot alterthe declinein
lung function, they decrease expiratory trapped air volume
and reduce dynamic hyperinﬂation during exercise as well
as (in the more severe cases) at rest [4]. They are prescribed
in both short- and long-acting forms for immediate (rescue)
and sustained relief, respectively.
Long-acting bronchodilators are recommended for
patients with moderate to severe COPD. In the largest trial
of a salmeterol, long-acting beta-2 agonist (LABA), Toward
a Revolution in COPD Health (TORCH), patients with a
mean forced expiratory volume in one second (FEV1)o f
44% of predicted (thusmostly severe COPD) were randomly
assigned tooneoffourtreatment armsfor3years: salmeterol
alone (50mcg twice daily), ﬂuticasone alone (500mcg
twice daily), the combination of both, versus placebo [11].
The salmeterol alone and combination arms each revealed
improved lung function, health-related quality of life, and
reduced exacerbation rates compared to the placebo arm.
No statistically signiﬁcant mortality reduction was seen.
However, the combination of ﬂuticasone and salmeterol
showed a trend towards a signiﬁcant (P = .052) reduction of
all-cause mortality by 17.5% in 3 years compared to placebo.
The eﬀects of the long-acting anticholinergic, tiotro-
pium, was assessed in a randomized trial Understanding
Potential Long-Term Impacts on Function with Tiotropium
(UPLIFT) [12]. Among patients with moderate (45%) and
severe (44%) COPD, tiotropium or placebo was added to
ongoing care, that is, inhaled corticosteroids, long-acting
beta-2 agonists, and/or theophylline, for a duration of 4
years. Tiotropium signiﬁcantly reduced the risk of exacerba-
tions and associated hospitalizations and respiratory failure
when added to usual care, while there was no diﬀerence in
t h ea n n u a lr a t eo fd e c l i n eo fF E V 1 or mortality between the
two groups [12]. However, in an intention-to-treat analysis
that assessed mortality after 4 years, the use of tiotropium
reducedallcausemortalityby13%(HR=0.87,95%CI0.76–
0.99, P<. 034) [13].
The combination of bronchodilators of diﬀerent classes
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side eﬀects [4]. For example, the combination of a LABA
and an anticholinergic (tiotropium) showed an improved
FEV1 by the end of a 12-week trial [14]. In another study,
the use of a short acting beta-agonist plus an anticholinergic
showed a greater and longer-lasting FEV1 improvement
when compared to each drug alone [15, 16]. However, no
clear data are available as to which long-acting bronchodila-
tor combination provides the best relief. Current guidelines
recommend weighing the risks and beneﬁts of each for the
individual patient [4].
Although pulmonary inﬂammation plays an important
role in the pathophysiology of the disease, inhaled corticos-
teroids (ICS) have not deﬁnitively been shown to decrease
the rate of lung function decline or change COPD morbidity
per se. However, the addition of an ICS may prove beneﬁcial
for some. In the TORCH study above, the combination of
a LABA plus ICS resulted in a decrease in the number of
exacerbations along with sustained beneﬁts in health status
and sustained improvement in FEV1 when compared to
placebo, salmeterol alone and ﬂuticasone alone [11]. This
combination is typically reserved for patients with GOLD
stages 3 and 4 with recurrent exacerbations, or for those
who have baseline eosinophilic component of their disease
or associated asthma.
Recently, this relationship of airway hyperresponsiveness
and the long-term eﬀects of ICS were also investigated in
a smaller randomized controlled trial of 114 patients with
moderate to severe COPD who had not used ICS for at
least 6 months [17]. Patients were randomized into four
treatment arms: ﬂuticasone for 6 months followed by 24
months of placebo, ﬂuticasone for 30 months, ﬂuticasone
and salmeterol for 30 months, or placebo only. Those treated
with placebo or with ﬂuticasone for the ﬁrst 6 months
had a decline in FEV1 of −87mL/year, and −65mL/year
respectively. Those treated with ﬂuticasone for 30 months or
ﬂuticasone and salmeterol had a signiﬁcantly reduced rate of
FEV1 decline (+7.3mL/year for the former and −16mL/year
for the latter). Overall, ﬂuticasone signiﬁcantly diminished
annual FEV1 decline over the last 2 years of the study when
compared with placebo (CI, 43 to 129mL/year; P<. 001).
It is important to note that 95% of these patients had
never used ICS, and the majority of patients had airway
hyperresponsiveness and revealed some acute reversibility of
FEV1. Thus, this study may be representing a subgroup of
COPD patients who may respond favorably to ICS [18].
A recent meta-analysis readdressed the possibility of
a favorable eﬀect on mortality when combining ICS and
bronchodilators in COPD [19]. Use of an ICS combined
with LABAdemonstrated a 20% reductionintotal mortality,
with a mortality risk ratio of 0.80 (95% CI, 0.69–0.94) [19].
However,useofaLABAortiotropiumalonedidnotdecrease
the mortality rate [19]. There is also concern that the use of
high dose ICS in patients with COPD may be associated with
an increased risk of pneumonia. The risks and beneﬁts of
these medications must be weighed for each patient [20, 21].
2.3. Nonpharmacologic Interventions: Pulmonary Rehabilita-
tion and Palliative Care. In order to eﬀectively treat patients
with COPD, it is important to understand the physical
decline, increased sense of isolation, changes in mood such
as depression, muscle wasting, and weight loss that can
aﬄict such patients [4]. Thus, comprehensive therapy must
include promoting a healthy life style including smoking
cessation, appropriate vaccinations, and encouragement to
remain physically active [22].
Pulmonary rehabilitation is designed to “reduce symp-
toms, optimize functional status, increase participation, and
reduce health care costs through stabilizing or reversing
systemic manifestations of the disease [23].” Data from
clinical trials reﬂect that pulmonary rehabilitation increases
peak workload by 18%, peak oxygen consumption by 11%,
andendurancetimeby87%frombaseline,butdonotchange
lung function or mortality [4]. Pulmonary rehabilitation
should be considered to be complementary to pharmacolog-
ical therapy and those with GOLD stages 2, 3, and 4 should
be encouraged to participate [4, 22].
The integration of palliative care among patients with
severe COPD is often overlooked. When compared to
patients with lung cancer, patients with severe COPD receive
less palliative care even though they suﬀer from the same
symptoms of dyspnea, depression, anxiety, pain, diﬃculty
sleeping, nutritional problems, cachexia, social isolation,
and functional disability [24]. Additionally, pain is often
underappreciated in severe COPD patients, despite the fact
that it is a symptom that is nearly as prevalent as in patients
withlungcancer(21%versus28%,resp.)[25].Givenitsmul-
tidisciplinary approach, pulmonary rehabilitation programs
provide a practical venue for incorporating palliative care for
these patients [24].
To date, the only therapy besides smoking cessation that
has been shown to statistically prolong survival in patients
with COPD is oxygen supplementation among those with
severe hypoxemia [22]. The administration of oxygen is
appropriate for COPD patients who have a PaO2 ≤ 55
mmHg or SaO2 ≤ 88%. A PaO2 between 55mmHg and
60mmHg or SaO2 ≥ 88% merits supplemental oxygen if
the patient has pulmonary arterial hypertension, peripheral
edema suggesting congestive cardiac failure, or polycythemia
(hematocrit > 55%). A survival beneﬁt was found in two
small studies for patients who qualiﬁed for oxygen therapy
and used it for greater than 15 hours per day [26, 27].
Nevertheless, the 2-year mortality is 49% in patients being
treated with oxygen [28].
W h i l et h ea d v e r s eh e a l t he ﬀects of COPD have impacted
people and health care systems worldwide, the ability to
modify or even halt disease progression remains limited.
Clearly earlier COPD case ﬁndings, diagnosis, and treatment
may be beneﬁcial and has fueled the development of novel
pharmacological interventions.
3.Novel PharmacotherapyforCOPD
Many of the current drugs used for COPD were adopted
from their application in asthma [1]. However, the patho-
physiology of COPD is markedly diﬀerent from asthma, and
the chronic inﬂammation seen in COPD is predominantly
from an inﬂux of neutrophils, macrophages, and CD84 Pulmonary Medicine
(cytotoxic T-helper) lymphocytes [1]. Eosinophils are seen
in lung biopsies but to a much lesser extent than in asthma.
CD8 lymphocytes are found in abundance in COPD but
have a diﬀerent role than in asthma [29]. By releasing
tumornecrosis factor-alpha(TNFα)andIL-12,macrophages
contribute to the destruction, remodeling, and continued
inﬂammation in the lung parenchyma. They are also a
source of matrix metalloproteinases that destroy collagen
and elastin [30]. The result is narrowing of small airways
from peribronchial ﬁbrosis and destruction of alveolar walls
[1]. There is a need for therapies that are formulated with
a better understanding of the targets speciﬁc to COPD. The
following describes pharmacotherapy that is currently under
study to modify COPD through mechanisms other than
bronchodilation.
3.1. Phosphodiesterase (PDE) Inhibitors. Inﬂammatory cells
such as neutrophils, CD8 lymphocytes, and macrophages,
express predominantly phosphodiesterase (PDE) type 4 [1].
PDE type 4 hydrolyzes cyclic adenosine monophosphate
(cAMP) in inﬂammatory cells. By inhibiting PDE type
4, intracellular cAMP concentrations increase which leads
to activation of protein kinase A, phosphorylation and
inactivation of target transcription factors, which ultimately
result in reduction of cellular inﬂammatory activity [31].
It is predicted that PDE type 4 inhibition will provide
better antiinﬂammatory activity in patients with COPD
than corticosteroids because the latter does not suppress
neutrophil activation or production of cytokines and
chemokines compared to the former [31]. While theo-
phylline is a nonspeciﬁc PDE inhibitor (thus with a large
side-eﬀect proﬁle including diarrhea, seizures and cardiac
arrhythmias), several new drugs have been tested that target
PDE type 4 speciﬁcally, notably cilomilast and roﬂumilast.
A dose-ranging study of the selective PDE type 4
inhibitor cilomilast in COPD patients showed signiﬁcant
improvements in FEV1, although quality of life measures
were not diﬀerent [32]. The safety and eﬃcacy of cilomilast
(15mg twice daily) was evaluated in a double-blindplacebo-
controlled study and showed signiﬁcant increase in FEV1
as well as fewer exacerbations over a 24-week period [33].
Gastrointestinal side eﬀects (nausea and diarrhea) were
greater in the ﬁrst 3 weeks of the study in the treatment
arm [33]. Cilomilast has been evaluated in three additional
multicenter, randomized, placebo-controlled phase III trials.
T h ec h a n g eo fF E V 1 (from 30–40mL) compared to placebo
was signiﬁcant in only two of the four studies. An increase in
exacerbation-free survival and decrease of the relative risk of
level 2 or 3 exacerbations were signiﬁcant in only two of the
four trials [34]. Overall, these studies did not show as large
of improvements in FEV1 as was expected based on phase II
trials [34].
Roﬂumilast is a more potent PDE type 4 inhibitor com-
pared to cilomilast [35]. In a phase III multicenter placebo-
controlled trial, 1411 patients were randomly assigned to
receive roﬂumilast 250mcg, roﬂumilast 500mcg, or placebo
daily for 24 weeks [31]. Postbronchodilator FEV1 at the
end of treatment signiﬁcantly improved for both groups of
roﬂumilastwhencomparedtoplacebo(74mLwiththelower
dose and 97mL with the higher dose medication). Both
groups suﬀered fewer mild exacerbations while moderate
to severe exacerbations were unchanged [31]. The most
common side eﬀects were also diarrhea and nausea.
Two randomized clinical trials on the use of Roﬂumilast
compared to placebo were published in 2009 [36]. Patients
in these studies had COPD with severe airﬂow obstruction,
documented cough and sputum production, and a history
of frequent COPD exacerbations in the past year. In pooled
analysis, the prebronchodilator FEV1 increased by 48mL
among those with the treatment drug, a statistically sig-
niﬁcant improvement compared to placebo [36]. Moderate
to severe exacerbations were also signiﬁcantly less in the
treatment arm. Some of the same authors published the
results of another set of trials that compared the use of
roﬂumilast to placebo when added to either salmeterol or
tiotropium [37]. When compared to placebo, the addition
of roﬂumilast to salmeterol was associated with a 49mL
prebronchodilator FEV1 increase, and an 80mL increase
when added to tiotropium. Moderate tosevere exacerbations
were noted to be signiﬁcantly less only when compared to
salmeterol [37]. Side eﬀects such as nausea, diarrhea and
weight loss contributed to greater patient withdrawal [37].
While results with roﬂumilast are encouraging, the USA
Food and Drug Administration (FDA) issued a response
letter requesting further information and analyses from the
manufacturers in May 2010 [38]. The drug has however
been granted marketing authorization by the European
Commission for several European countries since July 2010
[39].
3.2. N-Acetylcysteine (NAC). NAC has indirect and direct
antioxidant properties [40]. Its free thiol group reacts with
radical oxygen species (ROS). The presence of ROS has
been shown to decrease collagen and elastin formation as
well as increased IL-1 and IL-8 production, thus enhancing
inﬂammation [40].NACexertsindirect antioxidanteﬀectsas
a precursor to glutathione (GSH), a tripeptide that protects
against both internal toxins (agents from aerobic respiration
and metabolism of phagocytes) as well as external toxins
(components of cigarette smoke and pollution) [40]. Some
of the oxidant-antioxidant eﬀectsof NAC in the lung include
increased lung lavage levels of GSH, decreased superoxide
anion production by alveolar macrophages and decrease in
vitro adhesion of Haemophilus inﬂuenza and Streptococcus
pneumoniae to oropharyngeal cells [40–43].
Meta-analyses have shown that oral intake of NAC
decreases exacerbation in patients with chronic bronchitis
[44,45].However, in a large,randomized placebo-controlled
study, there was no improvement in lung function nor a
decrease in the frequency of exacerbation with a daily oral
administration ofNAC(600mg)toCOPDpatients[46].The
risk of exacerbations was nevertheless lower in the treatment
arm among patients not taking inhaled corticosteroids (HR
0.79, 95% CI 0.631 to 0.989) [46]. This study has been
criticized because of the low dose of NAC that was admin-
istered. Patients with moderate-severe COPD on 1200mgPulmonary Medicine 5
versus 600mg daily of NAC demonstrated a more eﬀective
normalization of C-reactive protein levels and decreased
serum IL-8 levels [47] .F u r t h e rt r i a l sw i t hh i g h e rd o s e so f
NAC are needed before a conclusive recommendation of
NAC therapy in COPD can be made.
3.3. TNFα Inhibitors-Inﬂiximab. Tumor necrosis factor
(TNF)α is an ubiquitous cytokine. Given its ability for
chemotaxis and activation of macrophages and neutrophils,
TNFα is an attractive target in the eﬀort to decrease inﬂam-
mation in COPD patients with elevated TNFα levels [48].
Such increased levels in advanced COPD may contribute to
skeletal muscle apoptosis and thus muscle wasting [49].
Inﬂiximab, the humanized monoclonal antibody direct-
ed against TNFα, was used in a multicenter, randomized,
double-blindplacebo-controlleddose-ﬁndingstudy.Patients
with moderate-severe COPD were given inﬂiximab (3mg/kg
or 5mg/kg versus placebo over a 24-week period [50].
While well tolerated, there was no signiﬁcant improvement
in the primary endpoint of disease-related health status,
or in secondary outcomes such as risk of exacerbations.
Though not statistically signiﬁcant, the authors found a
greater number of cases of cancer and pneumonia in the
treatment groups [50]. There may yet be a beneﬁt in using
this therapy in severe COPD with a wasting syndrome, but
the increased number of malignancies is of concern, and
further study is warranted [50].
3.4. ABX-IL8. The use of monoclonal antibody recognizing
interleukin (IL)-8 has been assessed in vitro and has been
hypothesized to reduce neutrophil migration and activation
in the airways and lung tissue [51]. To date, there is only
one randomized, double-blind placebo-controlled trial that
utilized this approach in moderate-severe COPD [51]. In
this study, three IV infusions of a human monoclonal
IgG2 antibody directed against human IL-8 (ABX-IL8) or
placebo infusion were administered over a three-month
period.Astatisticallysigniﬁcantimprovementintheprimary
outcome measure, dyspnea (as measured by the Transitional
Dyspnea Index) was found in the ABX-IL8 group versus
placebo [50]. However, there were no signiﬁcant diﬀerences
in lung function parameters, health status, or 6-minute
walk distance. Adverse events were similar between the two
groups, and the drug was well tolerated overall. This pilot
study emphasizes the potential importance of addressing the
inﬂammatory component of COPD.
3.5. Antileukotriene Drugs. Neutrophilic inﬂammation is
likely a signiﬁcant cause of mucus hypersecretion and
contributes to the destruction or remodeling of the lung
architecture as seen in COPD. Drugs suppressing neutrophil
inﬂux into the lungs make an attractive untapped approach
to preserving lung function in COPD. High levels of
leukotriene B4 (LTB4), a proinﬂammatory derivative of
arachidonic acid, have been found in the sputum of patients
with COPD [1]. LTB4 is both a chemoattractant and an
activator of neutrophils [52].
The eﬀects of a leukotriene synthesis inhibitor,
BAYx1005, among patients with COPD were assessed
in a small phase II trial [53]. After 14 days of treatment,
a signiﬁcantly greater median reduction in sputum LTB4
compared to placebo, though no signiﬁcant diﬀerence was
found in the absolute LTB4 concentrations between the
two groups [53]. Inhibition of leukotriene synthesis may
aﬀect neutrophilic bronchial inﬂammation in patients with
COPD, and further studies are warranted for this class of
medications [53].
3.6. Prophylactic Use of Macrolides. Macrolides are now
used for chronic diseases such as diﬀuse panbronchiolitis,
noncystic ﬁbrosis bronchiectasis, asthma, and cystic ﬁbrosis
to reduce airway inﬂammation [54]. Macrolides have both
antibacterial and antiinﬂammatory activity, and the latter
is evident even in low inhibitory concentration for airway
bacteria suggesting that the two may have independent
eﬀects [55].
Over the past decade, an increasing body of evidence
has suggested a beneﬁcial role in the chronic use of
macrolides for patients who suﬀer from frequent COPD
exacerbations [56, 57]. The largest trial to date was a
randomized, double-blind placebo-controlled study of ery-
thromycin given 250mg twice daily over a 12-month period
to patients with moderate-severe COPD [55]. The treatment
and placebo groups did not diﬀer from each other with
regards to stable FEV1, sputum IL-6, IL-8, bacterial ﬂora,
serum C-reactive protein or serum IL-6. However, there was
a statistically signiﬁcant reduction in exacerbations over the
one-year period in the treatment group [55]. While current
guidelines for the treatment of COPD do not endorse the
chronic use of antibiotic therapy, an increasing number of
studies support the use of macrolides at least among those
with the symptoms of chronic bronchitis and an increased
number of yearly COPD exacerbations.
3.7. Vitamin D. A link between vitamin D deﬁciency and
several chronic illnesses such a malignancies, autoimmune
diseases, infectious and cardiovascular illnesses has been
suggested but remains controversial [58]. In studies exam-
ining vitamin D levels in COPD, a review of spirometric
data from the NHANES III showed a positive relationship
between serum levels of 25-hydroxyvitamin D (25-OHD)
and pulmonary function (assessed by FEV1 and FVC)[59].A
cross-sectional study found that more than 50% of patients
awaiting lung transplant were vitamin D deﬁcient [60].
In light of the growing interest in this ﬁeld, Janssens and
colleagues measured serum 25-OHD levels in 414 patients
with COPD [58]. They found that decreased 25-OHD
levels correlated signiﬁcantly with decreased FEV1.W h e n
compared to smokers with normal lung functions, 60% and
77% of patients with GOLD stage 3, and 4, respectively,
were deﬁcient in 25-OHD levels. The authors also further
characterized the patients according to their vitamin D-
binding gene variants and those at increased risk of vitamin
D deﬁciency[58].Although replacementhas yet tobe shown
to modify COPD, the low-side-eﬀect proﬁle of vitamin6 Pulmonary Medicine
D makes it an attractive potentially therapeutic agent for
further research.
4.Surgicaland Minimally Invasive
(Nonsurgical)Approaches
4.1. Surgery. Lung-volume-reduction surgery (LVRS) was
initially proposed as a palliative treatment for those with
severe emphysema. In 2003, the National Emphysema Treat-
ment Trial (NETT) research group evaluated the eﬀects of
LVRS with a goal of better understanding which patients
would beneﬁt from this intervention [61]. They found
a survival advantage among former smokers with upper
lobe predominant emphysema and low baseline exercise
capacity (NETT). Exercise capacity was improved by 10W
in 28, 22, and 15% of LVRS patients at 6-, 12-, and
24-month followup respectively. This was compared to
4%, 5%, and 3% 10W improvement in patients in the
medical therapy group [61]. The LVRS group was also
more likely to have improved 6-minute walk distance,
FEV1% predicted, level of dyspnea, and disease-speciﬁc and
general quality of life results compared to the medical group
[61].
The NETT research group also analyzed the morbidity
and mortality data. The incidence of overall mortality
within 90 days was 7.9% (95% CI, 5.9–10.3) in the surgery
group compared to 1.3% (95% CI, 0.6–2.6) in the medical
therapy group (P<. 001), and a predictor of mortal-
ity was having nonupper lobe predominant emphysema.
Among patients not labeled high risk, 90-day mortality
was 5.2% in the surgery group as compared to 1.5%
in the medical therapy group (P = .001). Morbidity
was higher among older patients, those with lower FEV1
(<20%) or lower DLCO (<20%) [61]. The rate of at least
one postop complication within 30 days was 58.7%, with
the most common ones being arrhythmias, pneumonias,
and reintubations. Air leaks were documented in 90% of
surgical patients, and this prevalence and duration of air
leaks was increased by patient factors such as increased
airﬂow obstruction, use of inhaled corticosteroids, and lower
diﬀusion capacity [62]. Furthermore, 28.1% of patients were
hospitalized, living in a nursing home or rehabilitation
facility, or unavailable for interview at 1 month after LVRS
[61].
4.2. Minimally Invasive (Nonsurgical) Approaches. Estimates
of the number of patients who might beneﬁt from LVRS
or lung-volume reduction (LVR) using bronchoscopic min-
imally invasive approaches vary wildly from a total of 1.35
million patients to several hundred suitable patients per year
[10, 63]. The cost per procedure using the latter approach
is estimated at between $12,000 to $20,000 [10]. LVRS may
be beneﬁcial for a subgroup of patients with severe COPD,
but its risks can signiﬁcantly outweigh the beneﬁts for a
large number of the COPD population. Thus, nonsurgical
minimally invasive alternatives to LVRS are being explored.
The use of endobronchial blockers, bypass methods, valves
and sealants will be discussed here.
4.3. Endobronchial Blockers (Plugs). Mechanical blockers
were used in 8 COPD patients [64]. They were designed
to occlude the distal airway, resulting in distal parenchymal
collapse and thus LVR. The initial blockade was performed
via detachable, siliconeballoons, ﬁlled with contrast material
to allow for radiologic identiﬁcation. However, poor perfor-
mance due to migration (ﬁve episodes in 3 patients), and
in one case dislodgement and expectoration of the balloon
i nr e c o v e r y ,p r o m p t e dt h ea u t h o r st os w i t c ht os t a i n l e s s
steel wire stents containing biocompatible sponges [64]. The
increased rate of blocker migration, risk of postobstructive
pneumonia, and need for repeat procedures appear to have
limited further development of this modality [65].
4.4. Bronchial Fenestration and Airway Bypass. The mech-
anism underlying airway bypass entails constructing arti-
ﬁcial pathways (fenestrations) through the bronchial wall
into the surrounding parenchyma, and placing a stent to
maintain patency[66].The formation ofthenew conducting
expiratory airways allows for trapped air to escape via a
less resistant and nonobstructed path. The feasibility of
this procedure was demonstrated when 12 human lungs
were removed at time of transplant, placed in an air-
tight ventilation chamber and the bronchus attached to a
pneumotachometer [67]. Using a ﬂexible bronchoscope, a
radiofrequencycathetercreatedpassagesinwhichstentswere
deployed. The FEV1 increased from an average of 245mL at
baseline to 447mL after the placement of three stents, and
to 666mL after placement of 5 stents, conﬁrming feasibility
of the concept [67]. The safety of the procedure was
assessed in 10 patientsundergoing lobectomiesfor neoplasm
[68]. The procedure was performed after thoracotomy and
immediately before resection, and entailed the use of a
bronchoscope to reach the target site, a doppler probe to
avoid blood vessels at the target site, and the development
of passages through the bronchial wall with a cautery probe
[68].Subsequently,theauthorsperformedtheprocedurein5
patients undergoing lung transplant for emphysema. A total
of 47 passages were created with 2 episodes of mild bleeding,
both controlled with suction and the topical application of
epinephrine [68].
The addition of drug-eluting stents to the fenestrations
was evaluated in vitro [69, 70]. With the use of paclitaxel-
eluting stent placement in the fenestrations among thirty-
ﬁve patients with severe COPD, adverse events included
pneumomediastinum in two patients and one episode of
major bleeding that resulted in the death of the patient.
The authors noted that this fatal hemorrhage was due
to stent placement away from the original spot identiﬁed
with the Doppler probe [70]. Two COPD exacerbations
occurred within one month of treatment and ﬁve respiratory
infections occurred in the ﬁrst week after intervention.
At 6-month followup, there was a statistically signiﬁcant
decrease in mean RV by 400mL and level of dyspnea as
measured by the modiﬁed Medical Research Council Scale.
The authors found lasting beneﬁt only in patients whose
baseline RV/TLC was below the median [70]. There was no
signiﬁcant improvementin FEV1,6-minute walk distance, orPulmonary Medicine 7
St. George’s Respiratory Questionnaire (SGRQ) [70]. Only
small trials thusfar havebeen abletoprovideinformation on
the safety as well as eﬃcacy of the use of airway bypass and
stents.Largerclinicaltrialswith longerfollowupperiodsmay
further elucidate beneﬁts, if any, and in the case of the latter,
also help identify suitable patient subgroups most likely to
beneﬁt including those with homogenous emphysema.
4.5. Endobronchial Valves. Endobronchial valves (EBV) are
one-way valves that prevent air from entering the airway
distally but allow for ventilation of the expired gas and
drainage of distal secretions [67]. To date, two-valve designs
have been studied in separate multicenter reports (Zephyr
EBV, Pulmonx Corp and IBV, Spiration, Inc.) [65, 71, 72].
The Zephyr EBV, formerly known as Emphasys EBV, consists
of a stent-like self-expanding retainer made of nitinol, which
is wrapped in molded silicone [71]. In the center of the
retainer is a duckbill one-way valve that allows outﬂow of
gas and secretions during exhalation but does not permit
air entry during inhalation [10, 71]. The EBV is compressed
via a loader system, placed onto a delivery catheter, and a
guidewire directs this catheter to the targeted area, all via the
working channel of a bronchoscope [71].
The Intrabronchial Valve (IBV; Spiration) is also made
of nitinol and has 5 distal anchors and 6 proximal support
struts that are covered by a synthetic polyurethane polymer
[72]. These strutsexpand toform anumbrella shape to allow
for sealed placement in the airway. Air and mucus are able
to ﬂow around the edges of the membrane. The valve has
two delivery system options via a loading device through the
working channel of a ﬂexible bronchoscope [72].
Several clinical trials have added understanding of the
feasibility and eﬃcacy of endobronchial valves. In a ret-
rospective analysis from nine centers in seven countries,
a total of 98 patients with heterogeneous involvement of
emphysema and average baseline values of predicted FEV1
of 30.1%, RV of 244.3%, TLC of 128.4%, and DLCO 32.7%
were enrolled [71]. A total of 396 valves were placed, with an
averageperpatient of4.0 (range 1–8).Statisticallysigniﬁcant
improvementswere noted inFEV1 (10.7 ± 26.2%, P = .007),
FVC (9.0 ± 23.9%, P = .024), RV (−4.9 ± 17.4%, P =
.025), and exercise tolerance (23.0 ± 55.3%, P<. 001) [71].
Therewere 8(8%)seriouscomplications(3pneumothoraces
requiring surgical intervention, 4 prolonged air leaks, and
one death). The patient who died developed progressive
pneumonia and died from respiratory failure on postproce-
dure day 25 [71]. Seventeenpatients had acute exacerbations
of COPD.
The EBV valve was next tested in The Endobronchial
Valve for Emphysema Palliation Trial (VENT) [73]. This was
a multicenter, randomized controlled trial of 321 subjects
with severe heterogeneous emphysema (220 treated with
Zephyr EBV and 101 treated as controls). At 6-month
followup, the treatment group had statistically signiﬁcant
improvements in the primary endpoints of FEV1 (+6.8%,
P = .002) and 6MWT (+5.8%, P = .019). There were
also signiﬁcant improvements in secondary outcomes of
St. George’s Respiratory Questionnaire (SGRQ) and BODE
index (a measure of body mass index, degree of airﬂow
obstruction, dyspnea, and exercise capacity) compared with
control [73]. The 6-month mortality was 2.8% among the
treatment group (zero in the control group), and cumulative
mortality rate over 1-year followup was 3.7% for the Zephyr
group and 3.5% for the control group (P = 1.000).
Complications related to the device were valve migration,
pneumoniadistaltothevalve,andgranulationtissue.Inﬁnal
review of various outcomes from this trial, the FDA advisory
panel recommended against approval of this device, citing
that the beneﬁts were not large enough to overcome the risks
[74].
The largest trial reported to date with the Spiration
IBV valves was in an open-label study [75]. A total of
98 patients were enrolled at 13 international centers over
a 3-year period with the intent of bilateral treatment of
upper lobe predominant emphysema. Bilateral treatment
was done in 95 of the 98 patients, and a total of 659
valves were placed [75]. While they did not ﬁnd statistically
signiﬁcant improvements in spirometry and lung volume
measurements at 3 and 6 month followup, the patients
SGRQ decreased by greater than 4 (a 56% improvement)
at 6 months. There were a total of 8 pneumothoraces,
one of which was a tension pneumothorax that occurred
on postprocedure day 4 and resulted in the death of the
patient [75]. There were no episodes of valve migration or
expectoration. The most common postprocedure adverse
event was bronchospasm, which resolved after one bron-
chodilator treatment in 3 cases but required several repeated
treatments in 2 other patients. In the latter two cases, the
bronchospasm lasted for 24 to 48 hours, resolved after
valve removal, and was assumed to be related to the valves
[75].
To date, trials utilizing bronchoscopic LVR do not con-
sistently show an improvement of spirometric values, yet the
subjects continue to report decreased dyspnea and improved
scores on their SGRQ. It is hypothesized that these symp-
tomatic beneﬁts are the result of physiologic changes other
than lung compliance, especially since many studies report
incomplete atelectasis of the intervened lobe (even with
the lobar exclusion approach as the goal) [65, 76]. Ventila-
tion/perfusion (V/Q) scintigraphy was performed following
unilateral placement of EBVs in 6 COPD patients who had
destruction of their left upper lobe [77]. By 90-day followup,
there was a signiﬁcant decrease in the ventilation and perfu-
sion of the targeted left upper lobe (P = .01 and .02) though
only one of the 6 achieved atelectasis of the targeted region.
Furthermore, the subjects had an increase in the ventilation
and perfusion of the contralateral lung [77]. Placement of
the valve leads to reduced ventilation, while concomitant
decreased perfusion may be the result of subsequent hypoxic
vasoconstriction of the same region [77]. Furthermore, the
beneﬁcial eﬀectsecondary to a reduction in physiologic dead
space leads to more eﬃcient ventilation, and the reduced
hyperinﬂation may divert airﬂow to less obstructive airways
[76].
Currently endobronchial valves are not approved by
t h eF D Af o rt h eu s ei np a t i e n t sw i t he m p h y s e m a .L a r g e r ,
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better assess the role they may play as a minimally invasive
alternative therapy in LVR.
4.6. Biologic Lung Volume Reduction (Sealants). The use of
a ﬁbrin-based glue to collapse, scar, and seal oﬀ target
regions of abnormal lung was ﬁrst described in sheep [78].
The sealant occludes the airway distally, causes resorption
atelectasis, and subsequent airspace inﬂammation followed
by remodeling and scarring [65]. An open-label phase 1
trial deemed the use of the sealant in COPD patients
safe [79]. The sealant was placed in either two or four
unilateral pulmonary segments in6 men with heterogeneous
emphysema. There were no serious complications and all
patients were discharged on posttreatment day 1 [79].
Since then, three phase-two trials have been summarized
[80]. Fifty patients were divided into two treatment groups
(28 in the 10mL of sealant group and 22 in the 20mL
of sealant group). A ﬂexible bronchoscope was used to
advance into the selected subsegmental oriﬁce and wedged
in position. A dual lumen catheter was advanced into the
airways with the tip stationed 3-4cm distal to the bron-
choscope. The BioLVR ﬁbrinogen and thrombin solutions
were administered through the catheter over 10–15 seconds.
Immediatelyafterward, 60mLofairwasinjectedthroughthe
working channel of the bronchoscope to advance the reagent
distally. After 30 seconds, the bronchoscope was then moved
to the next intervention site [80].
No deaths were seen, but 4 serious adverse events
were documented.These consisted of pneumonia, aspiration
pneumonia followed by myocardial infarct, pleuritic chest
pain with subsequent fall related to analgesia use and
pulmonary embolism [80]. Forty-two patients experienced
leukocytosis, fever, and malaise, an expected side eﬀect due
to the inﬂammation that ensues from the procedure. The
primary endpoint of a signiﬁcant reduction in RV/TLC at 3
months was achieved in both dosing groups. At 6-months,
only the FEV1 remained signiﬁcantly improved compared
to baseline in the lower dose treatment group. However,
signiﬁcant improvements were sustained in all physiological
outcomes in the higher dose treatment group compared to
baseline [80]. The future of biologic or nonsurgical lung vol-
ume reduction needs further analysis by larger randomized
controlled trials with appropriate sham procedure.
5.Conclusion
While largely preventable, COPD is a progressive chronic
lung disorder with systemic consequences ranging from res-
piratory constraints, muscle wasting, chronic inﬂammation,
repeat infections and social limitations including isolation
and depression.
Current pharmacotherapy has been able to decrease
the number of exacerbations but remains inadequate at
halting disease progression. Developmentand clinicaltesting
of novel therapies are thus imperative in order to make
strides in this ﬁeld. This review of the state-of-the-art and
novel pharmacotherapy and experimental minimally inva-
sive interventions underscore the advances that have been
made in the past decade with regards to the amelioration
of symptoms and exercise limitations of COPD. Further
clinical studies are needed to bring the promise of improved
treatment and halting disease progression to fruition.
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